Picture of NeuroMetrix logo

NURO — NeuroMetrix Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapHigh Flyer

Momentum

Relative Strength (%)
1m-20.42%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-83.33%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of NeuroMetrix EPS forecast chart

Profile Summary

NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
April 25th, 2001
Public Since
July 22nd, 2004
No. of Shareholders
25
No. of Employees
20
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
6,645,397
Blurred out image of a map
Address
1000 Winter St, WALTHAM, 02451-1436
Web
http://www.neurometrix.com
Phone
+1 7818909989
Auditors
Moody, Famiglietti & Andronico, LLP

NURO Share Price Performance

Latest News for NURO

Upcoming Events for NURO

Q4 2021 NeuroMetrix Inc Earnings Release

Q1 2022 NeuroMetrix Inc Earnings Release

NeuroMetrix Inc Annual Shareholders Meeting

Similar to NURO

Picture of Accelerate Diagnostics logo

Accelerate Diagnostics

us flag iconNASDAQ Capital Market

Picture of Adapthealth logo

Adapthealth

us flag iconNASDAQ Capital Market

Picture of Aethlon Medical logo

Aethlon Medical

us flag iconNASDAQ Capital Market

Agendia NV

us flag iconNASDAQ Capital Market

Picture of Allied Healthcare Products logo

Allied Healthcare Products

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email